# **Product** Data Sheet

## Nintedanib-d<sub>8</sub>

Cat. No.: HY-50904S2 CAS No.: 1624587-87-6 Molecular Formula:  $C_{31}H_{25}D_8N_5O_4$ 

547.67 Molecular Weight:

Target: VEGFR; PDGFR; FGFR; Isotope-Labeled Compounds

Pathway: Protein Tyrosine Kinase/RTK; Others

Please store the product under the recommended conditions in the Certificate of Storage:

Analysis.

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 11.36 mg/mL (20.74 mM; Need ultrasonic and warming)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.8259 mL	9.1296 mL	18.2592 mL
	5 mM	0.3652 mL	1.8259 mL	3.6518 mL
	10 mM	0.1826 mL	0.9130 mL	1.8259 mL

Please refer to the solubility information to select the appropriate solvent.

### **BIOLOGICAL ACTIVITY**

Description Nintedanib- $d_8$  is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for

VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM,

respectively.

In Vitro Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as

tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to

affect the pharmacokinetic and metabolic profiles of  $drugs^{[1]}$ .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Hilberg F, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res, 2008, 68(12), 4774-4782.

3]. Roth GJ, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted ndolinone (BIBF 1120). J Med Chem, 2009, 52(14), 4466-4480.						
Caution: Product has not been fully validated for medical applications. For research use only.						
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemExpress.c	om		
	Address:	1 Deer Park Dr, Suite Q, Monm	outh Junction, NJ 08852, USA			

Page 2 of 2 www.MedChemExpress.com